This mechanism is completely distinct from growth hormones receptor-mediated actions
Monitor for unusual symptoms Pay attention to any changes in the 24-48 hours after injection
Based on these data, the FDA approved tesamorelin (marketed as EGRIFTA) for the reduction of excess abdominal fat in HIVassociated lipodystrophy, not as a general weightloss drug for the wider population. Tesamorelin Risks and Considerations Like all hormonemodulating therapies, tesamorelin carries potential risks, including fluid retention, joint pain, injectionsite reactions, and effects on glucose metabolism in susceptible patients
The outer abdomen, particularly the lower quadrants, contains substantial fat even in relatively lean individuals
What Makes Our B12 Injections Different: Unlike wellness spas or non-medical facilities, The Pur Health operates as a physician-led medical practice
Hydroxocobalamin | Drugs | BNF